Drug Profile
Adalimumab biosimilar - Outlook Therapeutics
Alternative Names: ONS-3010Latest Information Update: 01 Dec 2022
Price :
$50
*
At a glance
- Originator Oncobiologics
- Developer Ligand Pharmaceuticals; Outlook Therapeutics
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antineoplastics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Hepatoprotectants; Immunotherapies; Nootropics; Skin disorder therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunosuppressants; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Plaque psoriasis
- No development reported Cancer; Crohn's disease; Psoriasis; Rheumatoid arthritis; Ulcerative colitis
Most Recent Events
- 01 Dec 2022 No development reported - Phase-III for Cancer (SC) (Drug is not given in recent pipelines both the developer companies)
- 28 May 2020 No recent reports of development identified for phase-I development in Crohn's-disease(In volunteers) in Netherlands (SC, Injection)
- 28 May 2020 No recent reports of development identified for phase-I development in Psoriasis(In volunteers) in Netherlands (SC, Injection)